{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "result": {
    "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea006990719211888192b14f16a32b1b9ea1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_CGgt8tAHgzw1Nut0BX15QzvP\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_CGgt8tAHgzw1Nut0BX15QzvP"
          }
        ],
        "usage": {
          "promptTokens": 561,
          "cachedTokens": 0,
          "responseTokens": 31,
          "thinkingTokens": 16,
          "totalTokens": 608
        },
        "costUsd": 0.00163975
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea006990719515b88192bd63523b5fe3b3e8\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_AEOYaAva78osD3Az1baUpnSv\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_AEOYaAva78osD3Az1baUpnSv"
          }
        ],
        "usage": {
          "promptTokens": 1030,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 17,
          "totalTokens": 1091
        },
        "costUsd": 0.0026565
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea0069907199420081929d6a5c316f9a0ec6\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_RIXEQIcMDcpstZSQjcYOiu7Z\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea006990719942148192af5619186a9f091c\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_YAWHY6bcbzZDW8ZhUQrD4qWs\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea006990719942208192995eacebcd0dcb2f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_W3VBbeFpBZSjp7uMQWqMv8Nw\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea0069907199422c81928165ac292333e101\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_cK95wSmZkUocTU4qrrxYNCzG\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea006990719942388192bacc5085487a919b\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_vaV0Lc9Feyopysp5beDTK9xs\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_RIXEQIcMDcpstZSQjcYOiu7Z"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_YAWHY6bcbzZDW8ZhUQrD4qWs"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_W3VBbeFpBZSjp7uMQWqMv8Nw"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_cK95wSmZkUocTU4qrrxYNCzG"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_vaV0Lc9Feyopysp5beDTK9xs"
          }
        ],
        "usage": {
          "promptTokens": 1125,
          "cachedTokens": 0,
          "responseTokens": 165,
          "thinkingTokens": 0,
          "totalTokens": 1290
        },
        "costUsd": 0.00427875
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b291348192941d93b85e45e333\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\".\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_NOP6cQaEt5gWbZRqtBl7DJ9c\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_NOP6cQaEt5gWbZRqtBl7DJ9c"
          }
        ],
        "usage": {
          "promptTokens": 5320,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 1347,
          "totalTokens": 6711
        },
        "costUsd": 0.028783999999999997
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b3bb048192bccf5f24312ed91e\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"output\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_qZKrNMoTwFvdSkbnwh96HcB8\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_qZKrNMoTwFvdSkbnwh96HcB8"
          }
        ],
        "usage": {
          "promptTokens": 6730,
          "cachedTokens": 6528,
          "responseTokens": 42,
          "thinkingTokens": 0,
          "totalTokens": 6772
        },
        "costUsd": 0.0020839
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b8cc6881928cef56b98bcfbcdc\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_TgY0UbDaLKli2DVd87F2oX2g\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b8cc788192b9f7c383ca58d23f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_h9An8CfDM2Zv7irIqofnrjxk\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b8cc808192a812e21ed9059f76\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_KEOrQ1py6Tq9vv1TcbKwBvEP\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071b8cc8c8192b9037144c6174e08\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"offset\\\":0,\\\"limit\\\":2500}\",\n  \"call_id\": \"call_Aapwo8qvrr9XW2YoU0HUqZYy\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_TgY0UbDaLKli2DVd87F2oX2g"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_h9An8CfDM2Zv7irIqofnrjxk"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_KEOrQ1py6Tq9vv1TcbKwBvEP"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 2500
            },
            "output": "L1: {}",
            "callId": "call_Aapwo8qvrr9XW2YoU0HUqZYy"
          }
        ],
        "usage": {
          "promptTokens": 6802,
          "cachedTokens": 0,
          "responseTokens": 137,
          "thinkingTokens": 82,
          "totalTokens": 7021
        },
        "costUsd": 0.0149695
      },
      {
        "step": 7,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071e9297c8192870d3f1ce11a794e\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 immune checkpoint blockade.\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Pooled across repeat experiments to assess tumor control with intratumoral mRNA vaccine combined with anti-PD-L1 treatment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort (vaccine only, ICI only, vehicle)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched control conditions (vaccine-only, ICI-only and vehicle) pooled across experiments to contextualize combination-therapy effects.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-retrospective\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Retrospective cohort of metastatic patients treated with immune checkpoint inhibitors, stratified by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-vaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human vaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"43 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, compared for outcomes under ICI treatment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-unvaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human unvaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"87 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparator for vaccinated patients.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"Human analysis is retrospective and non-randomized; confounding likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients.\\\\\\\",\\\\n    \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit causal inference.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not translate one-to-one to human tumors.\\\\\\\",\\\\n    \\\\\\\"Mechanistic readouts were strongest in specific model systems only.\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_XxZq4PXEgswCI6z5wXnO08n3\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071e92990819283e1997b3aa2fd3f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with broader antigen display in the tumor immunopeptidome.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L28\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L29\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value under ICI\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"No comparator value reported (N/A)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In the retrospective human cohort, vaccinated patients showed improved survival under ICI treatment with a reported p-value of 0.01.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L30\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Tumors showed a marked induction of a type I interferon response after mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L31\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"PD-L1 expression increased, consistent with heightened engagement of the checkpoint axis.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L32\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"CD8+ T-cell density increased with combination therapy, indicating greater immune infiltration in tumors.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L33\\\\\\\"]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_eUoNtIO8XnoFsdnm5HZLyAFa\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071e9299881928f5e507a01ae73c4\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The study combines preclinical mouse tumor experiments with a retrospective human cohort to evaluate whether mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"strong\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L14\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L15\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The human component is explicitly retrospective, so it can support association but not definitive causal effects of vaccination on ICI outcomes.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination is associated with broader antigen presentation, including higher fractions of tumor proteins detected in the immunopeptidome and MHC-I peptidome.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L28\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"These values are reported in a structured summary table; additional details on experimental conditions and variance are not provided in the report excerpt.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status is associated with improved survival (p=0.01).\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"3. Human retrospective metastatic cohort: 130 patients total.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L21\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Because the cohort is non-randomized and retrospective, residual confounding and differences in care pathways could contribute to the observed survival association.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Type I interferon signaling is a proposed and experimentally supported mechanism for sensitization, and blocking IFNAR1 removes the benefit.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report summarizes the mechanistic chain at a high level; the extent to which this mechanism generalizes across tumor models and to humans is uncertain.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination increases PD-L1 pathway activity, supporting a rationale for combining vaccination with checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L32\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L45\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"PD-L1 increases can have multiple interpretations; the report does not provide detailed context (tumor models, timing, or variability) for this summary statistic.\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_K9hRyrO5pBsj2Oe9JhIK3lp3\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0e9e8919045697ea00699071e929a08192a16b74752d594d33\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"mRNA vaccination inside tumors may make checkpoint therapy work better\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (a kind of cancer immunotherapy) can lead to long-lasting responses for some people, but many tumors do not respond because they are not well “seen” by the immune system. This study explored whether injecting an mRNA vaccine directly into a tumor could create a local inflammatory signal dominated by type I interferons, which can boost antigen processing and presentation. In mouse tumor models, the authors report changes consistent with stronger immune priming, including broader peptide display on MHC-I and increased markers linked to responsiveness to anti-PD-L1 therapy. The paper also includes a retrospective (non-randomized) analysis of metastatic patients treated with checkpoint inhibitors, comparing outcomes by prior SARS-CoV-2 mRNA vaccination status, where a survival difference is reported. Overall, the work supports a biologically plausible strategy—using an mRNA-triggered inflammatory state to “sensitize” tumors—while emphasizing that prospective randomized trials are needed before changing clinical practice.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"Tests intratumoral delivery of an mRNA vaccine as a way to prime tumors for anti-PD-L1 therapy.\\\\\\\",\\\\n    \\\\\\\"Links sensitization to a type I interferon-rich state and broader MHC-I peptide presentation.\\\\\\\",\\\\n    \\\\\\\"Adds a retrospective human cohort comparison by SARS-CoV-2 mRNA vaccination status under ICI treatment.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human patient analysis is retrospective and non-randomized, so confounding can explain part of the association.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to starting checkpoint inhibitors varied, complicating interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse tumor model findings may not translate directly to every human cancer type or clinical setting.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic signals were strongest in specific model systems rather than uniformly across all settings.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A drug that releases brakes on immune cells (such as anti-PD-1/PD-L1 therapies) to help them attack cancer.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Delivered directly into a tumor, aiming to create a strong local immune effect where cancer cells are located.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signaling molecules often triggered by viral sensing that can promote inflammatory and antigen-presentation programs.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Antigen presentation (MHC-I)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal or tumor-derived targets.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immunopeptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The set of peptides presented on MHC molecules that can be detected experimentally, reflecting what the immune system can potentially “see.”\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would the same sensitization effect be observed in prospective randomized clinical trials in humans?\\\\\\\",\\\\n    \\\\\\\"Which tumor types and baseline immune states are most likely to benefit from intratumoral mRNA vaccination?\\\\\\\",\\\\n    \\\\\\\"What dosing, timing, and sequencing relative to checkpoint blockade best balance efficacy and safety?\\\\\\\",\\\\n    \\\\\\\"How durable are the immune changes (interferon signaling and antigen presentation) after intratumoral mRNA delivery?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_NRgonpVJAYqLySoAUnIMoOah\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 immune checkpoint blockade.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled across repeat experiments to assess tumor control with intratumoral mRNA vaccine combined with anti-PD-L1 treatment.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched control conditions (vaccine-only, ICI-only and vehicle) pooled across experiments to contextualize combination-therapy effects.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients treated with immune checkpoint inhibitors, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, compared for outcomes under ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparator for vaccinated patients.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non-randomized; confounding likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit causal inference.\",\n    \"Mouse model effects may not translate one-to-one to human tumors.\",\n    \"Mechanistic readouts were strongest in specific model systems only.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_XxZq4PXEgswCI6z5wXnO08n3"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the tumor immunopeptidome.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"No comparator value reported (N/A)\",\n      \"interpretation\": \"In the retrospective human cohort, vaccinated patients showed improved survival under ICI treatment with a reported p-value of 0.01.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed a marked induction of a type I interferon response after mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 expression increased, consistent with heightened engagement of the checkpoint axis.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"CD8+ T-cell density increased with combination therapy, indicating greater immune infiltration in tumors.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_eUoNtIO8XnoFsdnm5HZLyAFa"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"The study combines preclinical mouse tumor experiments with a retrospective human cohort to evaluate whether mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        }\n      ],\n      \"caveat\": \"The human component is explicitly retrospective, so it can support association but not definitive causal effects of vaccination on ICI outcomes.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination is associated with broader antigen presentation, including higher fractions of tumor proteins detected in the immunopeptidome and MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"These values are reported in a structured summary table; additional details on experimental conditions and variance are not provided in the report excerpt.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status is associated with improved survival (p=0.01).\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"3. Human retrospective metastatic cohort: 130 patients total.\",\n          \"line_ref\": \"L21\"\n        }\n      ],\n      \"caveat\": \"Because the cohort is non-randomized and retrospective, residual confounding and differences in care pathways could contribute to the observed survival association.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Type I interferon signaling is a proposed and experimentally supported mechanism for sensitization, and blocking IFNAR1 removes the benefit.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The report summarizes the mechanistic chain at a high level; the extent to which this mechanism generalizes across tumor models and to humans is uncertain.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Intratumoral mRNA vaccination increases PD-L1 pathway activity, supporting a rationale for combining vaccination with checkpoint blockade.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"PD-L1 increases can have multiple interpretations; the report does not provide detailed context (tumor models, timing, or variability) for this summary statistic.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_K9hRyrO5pBsj2Oe9JhIK3lp3"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may make checkpoint therapy work better\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (a kind of cancer immunotherapy) can lead to long-lasting responses for some people, but many tumors do not respond because they are not well “seen” by the immune system. This study explored whether injecting an mRNA vaccine directly into a tumor could create a local inflammatory signal dominated by type I interferons, which can boost antigen processing and presentation. In mouse tumor models, the authors report changes consistent with stronger immune priming, including broader peptide display on MHC-I and increased markers linked to responsiveness to anti-PD-L1 therapy. The paper also includes a retrospective (non-randomized) analysis of metastatic patients treated with checkpoint inhibitors, comparing outcomes by prior SARS-CoV-2 mRNA vaccination status, where a survival difference is reported. Overall, the work supports a biologically plausible strategy—using an mRNA-triggered inflammatory state to “sensitize” tumors—while emphasizing that prospective randomized trials are needed before changing clinical practice.\",\n  \"what_is_new\": [\n    \"Tests intratumoral delivery of an mRNA vaccine as a way to prime tumors for anti-PD-L1 therapy.\",\n    \"Links sensitization to a type I interferon-rich state and broader MHC-I peptide presentation.\",\n    \"Adds a retrospective human cohort comparison by SARS-CoV-2 mRNA vaccination status under ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human patient analysis is retrospective and non-randomized, so confounding can explain part of the association.\",\n    \"Vaccination timing relative to starting checkpoint inhibitors varied, complicating interpretation.\",\n    \"Mouse tumor model findings may not translate directly to every human cancer type or clinical setting.\",\n    \"Some mechanistic signals were strongest in specific model systems rather than uniformly across all settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A drug that releases brakes on immune cells (such as anti-PD-1/PD-L1 therapies) to help them attack cancer.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered directly into a tumor, aiming to create a strong local immune effect where cancer cells are located.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signaling molecules often triggered by viral sensing that can promote inflammatory and antigen-presentation programs.\"\n    },\n    {\n      \"term\": \"Antigen presentation (MHC-I)\",\n      \"definition\": \"A process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal or tumor-derived targets.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented on MHC molecules that can be detected experimentally, reflecting what the immune system can potentially “see.”\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would the same sensitization effect be observed in prospective randomized clinical trials in humans?\",\n    \"Which tumor types and baseline immune states are most likely to benefit from intratumoral mRNA vaccination?\",\n    \"What dosing, timing, and sequencing relative to checkpoint blockade best balance efficacy and safety?\",\n    \"How durable are the immune changes (interferon signaling and antigen presentation) after intratumoral mRNA delivery?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_NRgonpVJAYqLySoAUnIMoOah"
          }
        ],
        "usage": {
          "promptTokens": 7075,
          "cachedTokens": 6656,
          "responseTokens": 3443,
          "thinkingTokens": 64,
          "totalTokens": 10582
        },
        "costUsd": 0.050996049999999994
      },
      {
        "step": 8,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 10659,
          "cachedTokens": 10368,
          "responseTokens": 61,
          "thinkingTokens": 252,
          "totalTokens": 10972
        },
        "costUsd": 0.00670565
      }
    ],
    "totalCostUsd": 0.11211409999999998
  }
}
